CF
XERS icon

Corebridge Financial’s Xeris Biopharma Holdings XERS Stock Holding History

Corebridge Financial’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-68,698
Closed -$377K – 2840
2025
Q1 		$377K Sell
68,698
-1,018
-1% -$4.11K ﹤0.01% 1740
2024
Q4 		$236K Sell
69,716
-5,262
-7% -$16.9K ﹤0.01% 2082
2024
Q3 		$214K Sell
74,978
-463
-0.6% -$1.19K ﹤0.01% 2194
2024
Q2 		$170K Buy
+75,441
New +$152K ﹤0.01% 2298

Other funds holding XERS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Corebridge Financial's XERS Position: Q2 2025 in Review

Corebridge Financial sold out of Xeris Biopharma Holdings (XERS) in Q2 2025, closing a stake of 68,698 shares — an estimated $377K sold.

Corebridge Financial first reported a position in XERS in Q2 2024 and held it in 4 quarters. The position peaked at $377K in Q1 2025. 200 funds tracked by Wall St. Rank hold XERS as of Q2 2025.

  • Corebridge Financial reported no remaining Xeris Biopharma Holdings position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 68,698 Xeris Biopharma Holdings shares in Q2 2025, an estimated $377K.
  • Corebridge Financial first reported a position in Xeris Biopharma Holdings in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Xeris Biopharma Holdings position peaked at $377K in Q1 2025.
  • 200 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.